Servier Introduces Cosyrel: A Novel SPC for Hypertension and Post-MI Care
Servier India Pvt. Ltd. has launched a single-pill combination (SPC) of Bisoprolol/Perindopril in India under the brand name Cosyrel, which is approved as a substitution therapy for the treatment of hypertension and/or stable coronary artery disease (in patients with a history of myocardial infarction and/or revascularization) and/or stable chronic heart failure with reduced systolic left ventricular function in adult patients.
The Cosyrel tablet contains a Fixed-Dose Combination (FDC) of Bisoprolol Fumarate 5 mg and Perindopril Arginine 10 mg. Drugs Controller General of India (DCGI) has granted approval for the manufacture and marketing of FDC Bisoprolol Fumarate and Perindopril Arginine (5mg/5mg & 5mg/10mg) tablets.
The Pride Study evaluated the effectiveness of this FDC and found it significantly reduced systolic (SBP) and diastolic blood pressure (DBP), helping many patients reach their BP goals. Additionally, there were improvements in angina symptoms and reductions in heart rate (HR).
Most patients need two antihypertensive medicines to control blood pressure. A single-pill combination (SPC) of Bisoprolol and Perindopril has shown effective results in lowering blood pressure. Over two-thirds of patients reached their target BP (<140/90 mmHg) within one month, and nearly all achieved it by three months. The treatment is both effective and well-tolerated, making it a reliable option for patients at high cardiovascular risk.
Servier, an international pharmaceutical organization based in Mumbai, India, focuses on manufacturing and supplying pharmaceutical products in the fields of cardiometabolic health, neuroscience, venous disorders, and oncology, catering to both domestic and global markets.
Reference: Kobalava, Z., Kvasnikov, B., Burtsev, Y. et al. Effectiveness and Tolerability of Bisoprolol/Perindopril Single-Pill Combination in Patients with Arterial Hypertension and a History of Myocardial Infarction: The PRIDE Observational Study. Adv Ther 40, 2725–2740 (2023). https://doi.org/10.1007/s12325-023-02462-9
